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The ability of memory T cells to mount a recall response plays a key role in the ability of vaccinated animals to contain viral challenge. In
this study, we intensively monitored the expansion of SIV Gag-specific CD8+ T cells in peripheral blood and tissues of rhesus macaques
vaccinated with the attenuated strain SIVmac239D3 and challenged with the pathogenic viruses SIVmac239 or SIVsmE660. Although all
vaccinated animals were infected with challenge virus, peak levels of plasma viremia in vaccinees were decreased by 1.5 to 2 logs as
compared with naive controls. Decreased levels of plasma viremia in vaccinated animals were evident as early as 7 days post-challenge, well
before the expansion of SIV-specific CD8+ T cells. Expansion of SIV-specific CD8+ T cells was not observed in peripheral blood or tissues
until at least 14 days after infection and did not occur in most animals until after the initial peak of viral replication. The observation that
expansion of SIV-specific CD8+ T cells is delayed until 7 days or more after initial detection of viremia highlights fundamental limitations in
the ability of lentivirus-specific CD8+ T cells to mediate protection against challenge.
D 2005 Elsevier Inc. All rights reserved.
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Infection with viral pathogens characteristically results in
a rapid expansion of virus-specific CD8+ T cells, which in
many settings play a central role in containing viral
replication. In vaccinated or previously infected animals,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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results in higher peak levels of virus-specific CD8+ T cells
than in naive animals, although in the absence of neutraliz-
ing antibody responses, cytotoxic T lymphocyte (CTL)
responses do not generally provide sterile protection
(Ahmed and Gray, 1996; Doherty and Christensen, 2000).
Nonetheless, the rapid expansion of virus-specific CD8+ T
cells can result in prevention of disease induced by many
pathogens, including influenza, lymphocytic choriomenin-
gitis virus, cytomegalovirus, and pathogenic lentiviruses
such as simian-human immunodeficiency viruses (SHIV)
(Del Val et al., 1991; Flynn et al., 1998; Lau et al., 1994;
Shiver et al., 2002).05) 226–238
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proved to be one of the most effective strategies to induce
protection against SIV infection (Johnson and Desrosiers,
1998). Attenuated SIV strains defective in nef or other genes
have proved highly effective in inducing protection against
pathogenic, difficult to neutralize strains such as SIVmac251
and SIVmacJ5 following intravenous, rectal and vaginal
challenge (Almond et al., 1995; Connor et al., 1998; Cranage
et al., 1997; Daniel et al., 1992; Johnson et al., 1999). Despite
intensive study, the mechanisms by which attenuated SIV
strains induce protection against challenge remain poorly
understood. Most attenuated SIV strains induce relatively
potent SIV-specific antibody responses, which have in some
studies correlated with protection (Cole et al., 1997, 1998;
Johnson et al., 1999; Wyand et al., 1996). Infection with
attenuated strains such as SIVmac239Dnef or SIVmac239D3
also induces a diverse array of cellular immune responses,
including SIV-specific CTL responses (Dittmer et al., 1995;
Johnson et al., 1999; Lohman et al., 1994) and proliferative
responses (Dittmer et al., 1995; Gauduin et al., 1999), as well
as CD8+ T cell-mediated production of h-chemokines and
other soluble factors able to inhibit SIV replication (Gauduin
et al., 1998). Evidence for a role of SIV-specific CTL in
mediating protection induced by attenuated lentiviruses is
indirect, but includes correlations in some studies of CTL
activity with protection (Johnson et al., 1999; Miller et al.,
1997; Quesada-Rolander et al., 1996) and the fact that
protection can be mediated independently of neutralizingFig. 1. SIV plasma RNA levels after challenge of naive and vaccinated animal
intravenously with either SIVmac239 or SIVsmE660. SIV plasma RNA levels wer
The lower limit of detection was 400 copy equivalents (ceq) per ml of plasma.antibodies (Gundlach et al., 1998; Johnson et al., 1999;
Shibata et al., 1997). However, the precise role that SIV-
specific CD8+ T lymphocytes play in mediating protection
induced by attenuated SIV remains a matter of debate.
As one approach to better understand the role of SIV-
specific CD8+ T cells in mediating protection induced by
attenuated SIV, we undertook a study to examine the early
kinetics of SIV-specific CD8+ T lymphocyte responses in
macaques vaccinated with SIVmac239D3 and subsequently
challenged with either with a homologous (SIVmac239) or
heterologous (SIVsmE660) SIV strain. Based on prior
results documenting sterile protection against SIVmac251
(Wyand et al., 1996) and less complete protection against
the heterologous uncloned, pathogenic isolate SIVsmE660
(Wyand et al., 1999) in SIVmac239D3-vaccinated animals,
we hypothesized that intensive analysis of SIV-specific
CD8+ T cell responses in the early stages of successful and
unsuccessful pathogenic challenge might yield insights into
the kinetics of SIV-specific CD8+ T cell recall responses
and to whether SIV-specific CTL play a role in containing
the initial peak of viral replication. Because the dominant
sites of early SIV replication are in gut-associated lymphoid
tissue and lymph nodes (Veazey et al., 1998), we carried out
multiple serial biopsies of these sites in the first 2 weeks
after challenge, utilizing MHC class I tetramers to precisely
quantitate the frequency of SIV-specific CD8+ T cells.
Although sterile protection was not observed, SIVmac239D3
vaccinated animals contained viral replication of boths. Naive animals and SIVmac239D3 vaccinated animals were challenged
e quantitated by bDNA assays as previously described (Sodora et al., 1998).
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viral loads than naive controls. The fact that detectable levels
of SIV Gag-tetramer binding cells were present in vaccinated
animals prior to challenge allowed us to precisely time the
point at which SIV-specific CD8+ T cells began to expand
after challenge, an examination which has not been possible
in many prior studies of vaccinated animals post-challenge.
Expansion of SIV-specific CD8+ T cells was not observed in
peripheral blood or tissues until at least 14 days after
infection, and did not occur in most animals until after the
initial peak of viral replication.Results
Decreased peak and set point plasma viremia in
SIVmac239D3 vaccinated macaques
The vaccinated animals used in this study had all been
infected intravenously with SIVmac239D3 as neonates as
previously reported (Wyand et al., 1997). Three animals
developed sustained SIV-specific antibody responses, while
the fourth (61–95) developed only transient low-level
antibody responses to SIV and then seroreverted after 16
weeks (Wyand et al., 1997). Vaccine virus was neverFig. 2. Analysis of Mamu-A*01/Gag181–189 tetramer-binding cells in whole blood,
tetramer-binding cells was calculated by gating on CD3+CD8+ lymphocytes.recovered from PBMC cultures of animal 61–95, although
it was recovered from each of the 3 other vaccinated
animals in the first 5 months after infection. All 3
persistently SIVmac239D3-infected animals remained
healthy prior to challenge, with normal CD4+ T cell counts
and undetectable plasma SIV viral RNA loads (b400
copies/ml). Naive and vaccinated animals were then
challenged intravenously, in groups of 2, with either
SIVmac239 or SIVsmE660, approximately 62 months after
initial SIVmac239D3 vaccination. Based on the lack of
vaccine virus recovery and the lack of detectable SIV-
specific antibody or cellular immune responses (see below)
prior to challenge, we excluded the seroreverting animal
61–95 from analysis of viral loads after challenge in
vaccinees compared with controls. All naive and vaccinated
animals were infected after SIVmac239 or SIVsmE660
challenge. By day 8 post-challenge, mean plasma viral
RNA levels in naive animals were over 3 logs higher (mean
of log transformed viral load 5.6  106 copies/ml) than in
the 3 persistently infected SIVmac239D3-vaccinated ani-
mals (mean 1.8  103 copies/ml) (P b 0.05, Mann–
Whitney U test). Peak levels of plasma viremia at days 10
to 21 in the 3 vaccinated animals were decreased by 1.5 to 2
logs as compared with naive controls (P b 0.05) (Fig. 1),
and levels of plasma viremia at 42 days post-infection werelymph nodes and rectal biopsies. The frequency of Mamu A*01/Gag181–189
Table 1
Mamu-A*01/Gag 181–189 tetramer-binding CD8+ T lymphocytes in SIVmac239D3-vaccinated and naive animals challenged with SIVmac239
Days post-challenge % Gag tetramer-binding CD8+ cellsa
SIVmac239D3 NaRve
82–95 60–95 97D-248 97D-410b
Bloodc LNd REe Blood LN RE Blood LN RE Blood LN RE
14 naf 1.04 na na 0.60 na 0.00 0.01 0.06 0.05 0.01 na
7 0.48 0.58 0.03 0.05
0 0.30 0.59 0.03 0.03
3 0.45 0.51 0.00 0.00
8 0.30 1.20 na 0.50 0.47 na 0.00 naf 0.58 0.02 0.01 0.07
10 0.58 0.35 0.01 0.00
14 13.64 6.28 8.27 0.52 0.70 1.56 4.16 0.84 1.76 0.01 0.02 0.03
21 17.67 6.70 1.68 0.05
28 16.71 10.49 1.29 0.02
35 15.71 7.73 0.60 0.02
42 15.61 5.59
154 18.02 0.32 0.80 0.03
a Percent tetramer binding cells were calculated as a fraction of the total number of % CD3+CD8+ cells. Based on analysis of negative controls, levels z0.1%
in peripheral blood and lymph node and z0.2% in rectal biopsies were considered significant.
b Mamu-A*01-negative animal.
c Whole blood.
d Lymph node.
e Rectal biopsy.
f Not available: either not done or insufficient cells for analysis.
U.M. Abdel-Motal et al. / Virology 333 (2005) 226–238 229decreased by 2 to 3 logs (P b 0.05), subsequently falling to
undetectable levels in 2 animals. The data suggest that in
contrast to the control monkeys, the vaccinated animals
were better able to control SIV infection, with 2 of 3
persistently infected vaccinated animals achieving transi-
ently undetectable plasma levels of virus, which was
sustained to day 154 in one animal (905–95).Table 2
Mamu-A*01/Gag 181–189 tetramer-binding CD8+ T lymphocytes in SIVmac239D
Days post-challenge % Gag t
SIVmac239D3
905–95 61–95b
Bloodd LNe REf Blood LN
14 0.52 2.29 1.52 0.01 0.01
7 0.38 0.05
0 0.32 0.05
3 0.24 0.04
8 0.31 1.43 0.05
10 0.58 0.05
14 0.37 1.49 0.79 0.46 0.42
21 4.41 2.57
28 3.03 1.07
35 2.16 1.01
42 1.84 1.19
154 1.14 2.03
a Percent tetramer binding cells were calculated as a fraction of the total number o
in peripheral blood and lymph node and z0.2% in rectal biopsies were considere
b Animal 61.95 seroreverted 16 weeks after initial inoculation with SIVmac239D
c Mamu-A*01-negative animal.
d Whole blood.
e Lymph node.
f Rectal biopsy.
g Not available: either not done or insufficient cells for analysis.Kinetics of SIV Gag181–189-specific responses in peripheral
blood, lymph nodes, and rectal biopsies following challenge
SIV-specific CD8+ T cell responses were monitored
in peripheral blood, lymph node, and rectal biopsies
using a tetrameric complex of the rhesus Mamu A*01
molecule with an immunodominant Gag epitope correspond-3-vaccinated and naive animals challenged with SIVsmE660
etramer-binding CD8+ cellsa
NaRve
97D–255c 97D–143c
RE Blood LN RE Blood LN RE
na 0.01 0.01 na ndg nd na
0.04 0.00
0.01 0.05
0.04 0.06
na 0.05 na 0.05 0.04
0.03 0.00
0.41 0.01 0.03 0.02 0.02 0.03 0.01
0.01 0.04
0.03 0.02
0.01 0.01
0.03 0.02
f % CD3+CD8+ cells. Based on analysis of negative controls, levels z0.1%
d significant.
3.
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SIVmac239D3-vaccinated animals and one naive control
(79D–248) expressed the Mamu-A*01 allele. Prior to
challenge, 3 of 4 SIVmac239D3 vaccinated animals had
detectable Mamu-A*01/Gag181–189 tetramer-binding cells in
whole blood, comprising 0.1% to 0.9% of all circulating
CD8+ T lymphocytes (Fig. 2, Tables 1 and 2). The
SIVmac239D3-vaccinated animal (61–95) that had seror-
everted and remained antibody negative had undetectable
levels of SIV Gag181–189 tetramer-binding cells in peripheral
blood and lymph node (Table 2) prior to challenge. As
expected, the naive Mamu-A*01-positive animal prior to
infection and all Mamu-A*01-negative animals had unde-
tectable levels (b0.1%) of Mamu-A*01/Gag181–189 tetramer-
binding cells (Fig. 2, Tables 1 and 2). Since lymphoid tissue
and gut-associated lymphoid tissue are the dominant sites of
replication after acute SIV infection (Veazey et al., 1998), we
also examined the frequency of SIV Gag-tetramer binding
cells in these compartments. Although levels varied from
animal to animal, levels of SIV Gag181–189 specific cells
were generally higher in lymph nodes or rectal biopsies than
in whole blood (Tables 1 and 2). Remarkably, despite the fact
that SIV plasma RNA levels were first detectable at day 8Fig. 3. SIV-specific ELISPOT responses. Production of IFN-g was assayed after 4
Env. The frequency of SIV specific spots forming cells (SFC) was determined by
vaccinia virus NYCBH from the number obtained with the SIV-expressing vaccin
or SIVmac239 Env; animals challenged with SIVsmE660 were tested using SIVsand exceeded 104 copies/ml in 2 of 3 persistently infected
vaccinated animals by 10 days after challenge, an increase in
the frequency of tetramer-binding cells in peripheral blood of
vaccinated animals was first detected at day 14 only in a
single animal (82–95), the same point at which a significant
percentage of SIV Gag–specific T cells were first observed in
the naive Mamu-A*01-positive control (97D-248) infected
with SIVmac239 (Table 1). Increases above baseline in the
frequency of SIV Gag tetramer-binding cells in peripheral
blood of the 2 other SIVmac239D3 persistently infected
animals (60–95 and 905–95) were not detected until day 21.
Identical kinetics of expansion of SIV Gag-specific CD8+ T
lymphocytes were observed when frequencies were calcu-
lated as the absolute number of SIV Gag181–189 tetramer
binding cells per Al whole blood (data not shown). Similarly,
no increase in the frequency of Mamu-A*01-positive
Gag181–189 tetramer-binding cells was observed in lymph
nodes 8 days post-challenge in either of the 2 vaccinated
animals for which results were available, and only 1 of 3
animals showed an increase in SIV Gag-specific T cells in
lymph node at day 14 (Tables 1 and 2). Analysis of rectal
biopsies in persistently infected vaccinated animals at day 14
after challenge revealed a clear increase in the frequency of8 h stimulation of PBMC with recombinant vaccinia expressing SIV Gag or
subtracting the mean number of background spots obtained with the control
ia. Animals challenged with SIVmac239 were tested using SIVmac251 Gag
mH4 Gag/Pol or Env. nd = not done.
U.M. Abdel-Motal et al. / Virology 333 (2005) 226–238 231Mamu-A*01/Gag181–189 tetramer-binding cells only in ani-
mals 82–95, which also exhibited an increase in tetramer-
binding cells in peripheral blood at that time point. By day 21
after challenge, significant increases in the levels of Mamu-
A*01/Gag181–189 tetramer-binding CD8+ T cells were
observed in all vaccinated animals, with peak levels rising
to as much as 18% of circulating CD8+ T cells (Table 1 and
Fig. 2). In contrast, in the Mamu-A*01-positive naive
animal, the level of Mamu-A*01/Gag181–189 tetramer-bind-
ing CD8+ T cells was lower (1% to 4% of circulating CD8+
T cells), a level consistent with previous reports in naive
animals after SIV infection (Kuroda et al., 1999). Thus, in all
vaccinated animals, significant increases in the frequency of
SIV-specific CD8+ T cells were not detected until 14 to 21
days after infection, at least 1 week after the initial detection
of plasma viremia.
SIV-specific ELISPOT responses after challenge
PBMC from vaccinated and non-vaccinated animals
were isolated at different time points after challenge with
SIVmac239 or SIVsmE660 and production of IFN-g
following stimulation with SIV Gag or Env was
examined using ELISPOT assays. Prior to challenge, the
3 persistently SIVmac239D3-infected animals had levels
of SIV Gag-specific spot forming cells (SFC) between
122 and 216 per 106 PBMC, while no significant
responses (b50 SFC/106 PBMC) were observed in the
seroreverting animal 61–95 or the naive controls (Fig. 3).
Following SIVmac239 challenge, the SIVmac239D3-vac-Fig. 4. Gag-specific CTL activity following SIV challenge. CTL activity was dete
T); representative data for an E: T of a 40:1 are shown. Levels of lysis of controcinated animal 82–95 exhibited high levels of Gag-
specific SFC at days 14 and 42 post-challenge (2700
and 3300 SFC/106 PBMC) (Fig. 3), consistent with the
strong responses observed using the SIV Gag181–189
tetramer and CTL assays. Monkey 60–95, in contrast,
had lower levels of Gag-specific SFC (170–603 SFC/106
PBMC) at all time points (Fig. 3). Notably, although
animal 60–95 had only a low level of Gag SFC, this
animal had a one log lower viral load than animal 82–95
by day 42 after challenge. The persistently infected
SIVmac239D3 animal (905–95) challenged with
SIVsmE660, which had excellent control of viremia after
challenge, maintained relatively high levels of Gag-specific
SFC at days 7 to 28 post-challenge (517 to 977 SFC per
106 PBMC). The seroreverting animal (61–95) never
developed significant levels of Gag/Pol-specific SFC at
any time point after challenge (Fig. 3). In naive animals
challenged with SIVmac239, Gag-specific ELISPOT
responses varied between 98 and 650 SFC/106 PBMC
after challenge, whereas no detectable SIV Gag-specific
SFC were observed in the 2 naive animals challenged with
SIVsmE660 (Fig. 3). Levels of Env-specific SFC were
generally lower than observed for Gag, and when observed
(e.g., animal 905–95), displayed similar kinetics as Gag-
specific SFC (Fig. 3).
SIV-specific CTL responses after challenge
To complement the data obtained using MHC class I
tetramers and ELISPOT assays, we analyzed SIV-specificrmined in standard Cr51-release assay at multiple effector to target ratios (E/
l vaccinia-infected B-LCL ranged between 0 and 6%.
Table 3
SIV envelope-specific antibody titers before and after challengea
Day post-challenge Reciprocal of endpoint dilution titerb
SIVmac239D3 vaccinated NaRve
SIVmac239c SIVsmE660c SIVmac239 SIVsmE660
82–95 60–95 905–95 61–95 97D–255 97D–143 97D248 97D–410
14 12,800 25,600 3200 b50 b50 50 b50 b50
0 12,800 25,600 3200 b50 b50 b50 b50 b50
14 12,800 25,600 3200 b50 50 b50 b50 b50
28 204,800 102,400 204,800 6400 12,800 200 3200 12,800
155 409,600 819,200 409,600 306,900 102,400 204,800 204,800 102,400
a Plasma samples were analyzed for reactivity to SIVsmB7 viral envelope glycoproteins in a concanavilin A ELISA.
b Endpoint titers to viral envelope glycoproteins are reported as the last serial 2-fold dilution with an optical density twice that of normal monkey serum, or an
optical density of 0.1, whichever value was greater.
c Challenge strain of virus.
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antigen-specific stimulation. CTL responses against SIV
Gag were prospectively evaluated before and after challenge
with fresh PBMC stimulated with autologous B-LCL
infected with recombinant vaccinia viruses expressing SIV
proteins, as described previously (Johnson et al., 1997).
Although results varied between assays, all vaccinated
animals except 61–95 (the animal that seroreverted) had
detectable SIV-specific CTL activity in at least one of the
two pre-challenge assays (Fig. 4). Consistent with the
results obtained using the Mamu-A*01 Gag181–189 tetramer,
SIV-specific CTL activity increased at day 14 post-
infection. At later time points, SIV-specific CTL activity
continued to increase in the vaccinated animals with the best
control of viremia (60–95 and 905–95). Notably, although
the highest levels of SIV Gag181–189 tetramer-binding cells
(16%–18%) in peripheral blood were observed in animal
82–95, this animal had approximately 3-fold lower CTL
activity at day 42 than animal 60–95, which had an almost
3-fold lower level of Mamu-A*01 Gag181–189 tetramer-
binding cells (Table 1). All naive animals also had
significant levels of SIV-specific CTL on day 14 after
infection, which varied thereafter (Fig. 4). No significant
differences in CTL activity were observed in the
SIVsmE660 challenged animals using target cells express-Table 4
SIVmac251-specific neutralizing antibody titers before and after challenge
Day post-challenge Reciprocal of endp
SIVmac239D3 vaccinated
SIVmac239b SIVsmE660b
82–95 60–95 905–95 61–9
0 329 1001 988 b2
14 412 614 989 b2
28 2309 818 4465 130
154 5209 12,384 4021 43,74
a Neutralizing antibody titers are reported as the reciprocal serum dilution at whi
neutral red uptake. TCLA: T cell line adapted.
b Challenge strain of virus.ing SIV antigens from the SIVsmE660 related strain SIVsm
H4 (data not shown).
Analysis of SIV-specific antibody responses
Prior to challenge, all vaccinated animals, except the
seroreverting animal 61–95, had detectable levels of anti-
bodies (Table 3). Following challenge, a dramatic increase
in envelope-specific antibody levels was observed starting at
day 28 in all 3 persistently infected vaccinated animals,
rising to titers of 102,400 to 204,800, consistent with an
amnestic response (Table 3). In the seroreverting animal
61–95 and the naive controls, SIV envelope-specific
antibody responses were detected by day 28 post-challenge
in all animals, but were on average 1–2 logs lower than
antibody titers observed in the vaccinated animals. No
clear difference in antibody titers between SIVmac239 and
SIVsmE660 challenged animals was observed (Table 3).
Examination of neutralizing antibody titers to SIVmac239
and SIVsmE660 prior to and after challenge revealed no
significant neutralizing activity to either of these viruses
(not shown). Neutralizing antibody titers to T cell line
adapted SIVmac251 of between 300 and 1000 were found
in the 3 persistently infected SIVmac239D3-infected
macaques prior to challenge (Table 4). Increases in SIV-oint dilution titer to TCLA SIVmac251a
NaRve
SIVmac239 SIVsmE660
5 97D248 97D–410 97D–255 97D–-143
0 b20 b20 b20 b20
0 b20 b20 37 b20
4 262 1687 2181 1050
0 9418 7231 11,535 5588
ch 50% of cells were protected from virus-induced killing as measured by
U.M. Abdel-Motal et al. / Virology 333 (2005) 226–238 233mac251 neutralizing antibody titers were first detected at
28 days post-challenge, and at 154 days after challenge
ranged from 5200 to 43,740, with no significant difference
between vaccinees and naive animals.Discussion
To better understand the role that SIV-specific CD8+ T
lymphocytes may play in protection against challenge, we
carried out a detailed analysis of the frequency of SIV Gag-
specific CD8+ T cells in peripheral blood and tissues of
SIVmac239D3-vaccinated animals after challenge with
pathogenic SIV strains. We reasoned that intensive analysis
of kinetics of SIV-specific CD8+ T cell responses in the
early stages following challenge might yield insights into
the role of SIV-specific CD8+ T cells in containing the
initial peak of viral replication and set-point levels of vire-
mia. Although sterile protection against either SIVmac239
or SIVsmE660 was not achieved in animals vaccinated with
SIVmac239D3, we observed significantly lower peak and
set point levels of plasma SIV RNA after infection. Notably,
the expansion of SIV-specific CD8+ T cells in vaccinated
animals in peripheral blood was delayed until 7 to 14 days
after peak viremia, and similar kinetics of expansion were
observed in lymph nodes and rectal biopsies.
One of the hallmark characteristics of memory CD8+ T
cells is their ability to expand briskly after antigenic
stimulation, generally leading to more rapid viral contain-
ment (Ahmed and Gray, 1996; Doherty and Christensen,
2000). The rapid expansion of memory virus-specific CD8+
T cell responses to relatively high frequencies following
viral challenge appears to reflect both the increased fre-
quency of virus-specific cells and the more rapid prolifer-
ation of memory than naive T cells (Cho et al., 1999;
Doherty and Christensen, 2000). For instance, in mice
rechallenged with influenza, increases in the frequency of
virus-specific CD8+ T cells can be detected 2 days earlier
than in naive animals and subsequently rise to levels
approximately 3-fold greater than in naive animals (Flynn
et al., 1999). Several studies analyzing the kinetics of SIV-
specific CD8+ T cell responses after intravenous challenge
of vaccinated macaques have also revealed a more rapid
response than in naive animals, resulting in detectable
increases in the frequency of tetramer-binding cells 2 to 4
days earlier than observed in controls (Egan et al., 2000;
Seth et al., 2000). However, in these previous studies (Egan
et al., 2000; Seth et al., 2000), levels of SIV Gag181–189
tetramer binding cells were generally undetectable at the
time of challenge, thus precluding precise determination of
the time at which expansion of SIV-specific CD8+ T cells
began. In our study, the ability to follow baseline levels of
SIV Gag181–189 tetramer binding cells, which remained
unchanged for periods of 10 to 14 days or more after
challenge in the immunized animals, demonstrate that
expansion of SIV-specific CD8+ T cells is delayed untilapproximately 7 days after initial detection of plasma vire-
mia. These data are quite similar to those recently reported
by Davenport et al. (2004), who analyzed the kinetics of
expansion of Mamu-A*01/Gag181–189 tetramer-binding cells
in vaccinated animals after SHIV-89.6P challenge. Analysis
of lymph node biopsies and rectal biopsies in our study
revealed similar kinetics of expansion of SIV-specific CD8+
T cells in these sites, suggesting that the failure to detect an
increase in tetramer-binding cells in peripheral blood is not
due to sequestration of proliferating antigen-specific cells in
lymphoid tissues. Although we focused our quantitative
analysis of SIV-specific CD8+ T cells on cells able to bind
the Mamu-A*01-restricted Gag181–189 epitope, these data
were corroborated by analysis of CTL and ELISPOT
responses to Gag and Env in PBMC. Unfortunately, levels
of Mamu-A*-01/Tat28–35 tetramer-binding cells are unde-
tectable in the majority of animals that are chronically
infected with SIVmac239D3 (unpublished observations), so
we were not able to extend these observations using
tetramers other than Mamu-A*01/Gag181–189.
Several factors may account for the approximate 7 day
delay between the onset of detectable viremia and the
detection of Gag-specific CD8+ T cell expansion in
vaccinated animals, including delays in antigen processing
and presentation of SIV antigens to virus-specific CD8+ T
cells, delays in CD8+ T cell expansion following antigenic
stimulation, and delays in trafficking of SIV-specific CD8+
T cells from lymphoid tissues to peripheral blood. Incom-
plete information at present regarding the kinetics of these
processes in primates preclude an unequivocal answer to the
reason for this delay. In murine models of influenza
infection, delays in the expansion of virus-specific CD8+
T cell responses are believed in part to be due to the fact that
antigenic stimulation occurs in regional lymph nodes after
migration of antigen-presenting cells and memory T cells to
these sites (Doherty, 1997; Doherty and Christensen, 2000).
Delays in antigen processing within infected cells appear
unlikely to contribute significantly to this delay, since in
vitro studies have demonstrated that recognition of HIV-
infected CD4+ T cells can occur within approximately 24 h
after virus infection, roughly coincident with the detection
of virus production (Yang et al., 1996). Regardless of the
precise mechanism, this 7-day delay in essence provides the
virus with a head start of 5 to 7 replicative cycles prior to
expansion of SIV-specific CD8+ T cells. Although vacci-
nation of animals can increase the frequency of virus-
specific CD8+ T cell responses after virus challenge and
slightly accelerate the detection of virus-specific CD8+ T
cell responses, the limitations inherent in kinetics of
CTL expansion may in part explain the failure of vac-
cine approaches that induce only CTL responses to pro-
vide significant protection against SIV challenge (Horton
et al., 2002).
Comparison of pre-challenge and peak levels of tetra-
mer-binding cells prior to challenge in persistently
SIVmac239D3-infected animals also allows calculation of
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lenge, which varied between 12- and 30-fold in vaccinated
animals. This degree of expansion corresponds to between
3.6 and 4.9 cell division cycles, assuming the loss of
dividing cells to apoptosis during this expansion phase is
negligible. Recent studies in mice have shown that even a
brief contact of naive T cells with antigen results in 7 to 10
rounds of cell division in vitro, suggesting that once
triggered, naive T cells enter a preprogrammed phase of
proliferation even in the absence of continued antigenic
stimulation (Kaech and Ahmed, 2001; van Stipdonk et al.,
2001). A similar magnitude of proliferation corresponding
to 128- to 1024-fold expansion of antigen-specific cells
with a starting frequency of 0.3% to 0.5% would result in
CD8+ T cells specific for a single epitope comprising over
50% of the total body T cell pool and significantly disturb
T cell homeostasis. Different mechanisms are therefore
likely to control proliferation of memory T cell responses
after antigenic stimulation, resulting in lower overall levels
of proliferation than for naive cells.
Despite the failure of SIV-specific CD8+ T cells to
expand before day 14, levels of plasma viral RNA in
persistently infected vaccinees were 2 logs lower than naive
animals even as early as day 7 post-challenge. Several
possibilities may explain this observation. One possibility is
that CTL may be effective in inhibiting SIV replication even
without expansion, for example, through production of g-
chemokines and other soluble factors able to inhibit SIV
replication (Gauduin et al., 1998). Another possibility is
inhibition of SIV replication by antibody responses, as
suggested by the evidence that many attenuated SIV strains
induce relatively potent SIV-specific antibody responses,
which have in some studies correlated with protection
(Clements et al., 1995; Cole et al., 1997; Johnson et al.,
1999; Wyand et al., 1996). Finally, innate immune
responses such as natural killer cells or gamma-delta cells
that exert their effects during the early stages of infection
before the boosting of adaptive immune responses may
also play a role in the early control of viremia (Tenner-Racz
et al., 2004).
While there have been previous reports of induction of
sterilizing protection by attenuated SIV against challenge
with pathogenic SIV (Almond et al., 1995; Clements et al.,
1995; Connor et al., 1998; Cranage et al., 1997; Daniel et
al., 1992; Johnson et al., 1999; Wyand et al., 1996), our
results showed that none of the vaccinated animals
exhibited sterilizing immunity against SIVmac239 or
SIVsmE660 challenge. The failure to observe sterile
protection in SIVmac239D3-vaccinated animals may reflect
several factors, including: (1) less effective protection
induced by the more attenuated strain SIVmac239D3 as
compared with SIVmac239Dnef (Connor et al., 1998); (2)
the use of sensitive plasma SIV RNA assays in place of
quantitative viral culture assays, which in previous studies
have failed to detect viral replication in some challenged
animals with SIV plasma RNA levels as high as 105 copies/ml (Wyand et al., 1999); (3) the use of intravenous instead
of mucosal challenge, which has previously been reported
to result in better protection against more attenuated SIV
strains (Johnson et al., 1999); and (4) the delay of over 5
years between vaccination and challenge, whereas previous
studies examining protective immunity induced by
SIVmac239D3 have observed sterile protection following
intervals of no more than 1 1/2 years after vaccination
(Johnson et al., 1999; Wyand et al., 1996). Although the
fact that SIVmac239D3 can induce immunodeficiency
following infection of neonatal macaques with relatively
high dose inocula (Baba et al., 1995; Wyand et al., 1997)
raises the possibility that neonatal vaccination of macaques
with SIVmac239D3 may be less effective at inducing
protection against subsequent challenge than vaccination
of juvenile or adult macaques, we believe this possibility is
unlikely. First, all of the SIVmac239D3 infected macaques
reported here exhibited excellent control of attenuated virus
replication with no evidence for immunodeficiency. Second,
baseline levels of SIV-specific cellular and humoral immune
responses prior to challenge were quite similar to those ob-
served in juvenile or adult macaques infected with
SIVmac239D3 (Cromwell et al., 2000; Johnson et al.,
1999 and unpublished data). Similar levels of SIV-specific
neutralizing antibody responses have been observed in
macaques infected with SIVmac239D3 as neonates or
adults (Montefiori et al., 1996). Finally, a recent study
analyzing SIV plasma viral RNA levels in macaques
vaccinated with SIVmac239D3 as juveniles and subse-
quently challenged intravenously with SIVmac251 also
revealed a similar lack of sterile protection as observed
in the present study (unpublished data). However, despite
the fact that sterile protection was not observed,
SIVmac239D3-vaccinated animals efficiently contained
viral replication with significantly lower peak and set
point viral loads than naive controls.
Defining the early events following virus challenge has
important implications for our understanding of mechanisms
of protection and control of viremia in vaccinated macaques.
Our present results highlight the limitations that virus-
specific CD8+ T cells face in protecting the host against
challenge with SIV or HIV.Materials and methods
Animals, virus stocks, immunization, and challenge
Eight rhesus macaques were used in this study. Four of
them were naive and the other four had been infected
intravenously as neonates with SIVmac239D3 as previously
described (Wyand et al., 1997). All animals were housed
in the biocontainment facility at Primedica. Intravenous
challenge was carried out with either 10 animal infectious
doses SIVmac239 or 100 animal infectious doses of
SIVsmE660 as indicated. The preparation, titration, and
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have been described previously (Desrosiers et al., 1998;
Goldstein et al., 1994). The presence of the Mamu-A*01
MHC class I allele was determined using sequence-spe-
cific primer PCR as previously described (Knapp et al.,
1997).
Viral load analysis
Quantitation of SIV plasma RNA was performed by
bDNA assays as previously described (Chiron/Bayer Diag-
nostic, Emeryville, CA) (Sodora et al., 1998). The lower
limit of detection of this assay at the time this study was
performed was 400 copies per ml.
Cell isolation and mucosal biopsies
Blood for immunologic assays was collected in hepari-
nized CPT Vacutainer tubes (Becton Dickinson Vacutainer
Systems, Franklin Lakes, and NJ). Blood for flow cytom-
etry and complete blood counts was anticoagulated with
EDTA. Lymph nodes and rectal biopsies were collected in
phosphate-buffered saline (PBS). T cells from rectal
biopsies were isolated as previously described (Veazey et
al., 2000). Briefly, all rectal biopsies were incubated with 5
mM EDTA for 30 min, washed and incubated with 15 U/ml
collagenase (type II, Sigma) followed by mechanical
disruption with an 18 gauge-feeding needle. Intestinal
lymphocytes were then enriched by bilayer (35%/60%)
isotonic Percoll density gradient centrifugation (1000  g,
20 min) and the interface containing the lymphocytes was
collected. Lymphocytes were isolated from lymph nodes
by dissociation of tissue by mincing with scalpel blades
and gently pressing tissue fragments through nylon mesh
screens. All blood samples and biopsies were shipped
within 2–3 h of collection to the New England Primate
Research Center. Automated cell counts were performed
using a Series 9000 Hematology Series Cell Counter
(Serono Baker Diagnostics, Allentown, PA) using cell
size discriminators optimized for rhesus macaques.
Leukocyte differential counts were performed manually
by counting 100 white blood cells on a Wright’s stained
blood smear.
Flow cytometric analysis
Four-color flow cytometry was used for immunopheno-
typing of whole blood lymphocytes using standard proce-
dures as previously described (Cromwell et al., 2000).
Briefly, 200 Al of rhesus whole blood in 12  75 mm
polystyrene test tube (Falcon, Lincoln Park, NJ) was
incubated with the following monoclonal antibodies: 20 Al
of FITC-conjugated CD3, (clone SP34), 20 Al of PE-
conjugated CD4 (Leu-3a), 20 Al of PerCP-conjugated CD8
(Leu-2a), all from BD Biosciences (San Diego, CA). All
antibodies were mAbs of anti-human specificity that cross-react with rhesus antigens of the same specificity. Tetramer
staining was carried out using 10 Al of allophycocyanin-
conjugated Mamu-A*01/Gag181–189 tetramer (Allen et al.,
1998) as previously described (Cromwell et al., 2000).
Negative controls consisting of SIV-infected Mamu-A*01-
negative or uninfected Mamu-A*01-positive animals were
included in each flow cytometric analysis. Based on analysis
of these negative controls, levels of Mamu-A*01/Gag181–189
tetramer-binding cells of z0.1% CD8+ T lymphocytes in
blood and lymph node and z 0.2% CD8+ T lymphocytes in
rectal biopsies were considered significant. Stained cells
were fixed in 1% paraformaldehyde and analyzed on a
Becton Dickinson Immunocytometry Systems FACSCali-
bur. In general, a total of 200,000 events were acquired, and
analysis of tetramer-binding cells was carried out on
CD3+CD8+ gated lymphocytes. For rectal biopsies, the T
lymphocyte population was first identified by gating on
events based on CD3 expression and forward scatter and
analysis was then performed as for whole blood. In some
instances, the frequency of tetramer-binding T cells was
calculated by pooling results from replicate samples from
the same rectal biopsy specimen. Samples were only used
for analysis if a distinct tetramer-staining population of
CD3+CD8+ cells could be identified.
IFN-c ELISPOT assay
ELISPOT assays for IFN-g-secreting cells were per-
formed with a commercial kit (U-Cytech, Utrecht, The
Netherlands), based on a previously published technique
adapted for rhesus macaques (Gauduin et al., 1999; van der
Meide et al., 1995). Briefly, ninety-six-well flat-bottom
plates were coated with 50 Al/well of anti-IFN-g mAb MD-1
(U-Cytech) overnight at 4 8C. The plates were washed 10
times with PBST (PBS containing 0.05% Tween 20) and
blocked with PBS containing 1% BSA for 1 h at 37 8C.
Serial dilutions of freshly isolated PBMC (3  105, 1  105
and 3  104 cells per well) in R10 medium were plated in
duplicate, and infected with recombinant vaccinia viruses
expressing either SIVmac251 Gag and SIVmac239 enve-
lope (Env) (for SIVmac239 challenged animals), SIVsmH4
Gag/Pol and Env (for SIVsmE660 challenged animals) or
the control vaccinia virus NYCBH. After incubation for 48
h at 37 8C in 5% CO2 nonadherent cells were then removed,
and 200 Al/well of ice-cold deionized water was added to
lyse the remaining PBMC. Plates were incubated on ice for
15 min and washed 20 times with PBST. One hundred Al per
well of anti-IFN-g detector Ab (U-Cytech) was added, and
plates were incubated for 1 h at 37 8C before being washed
10 times with PBST. Fifty Al per well of GABA (U-Cytech)
was added for 1 h at 37 8C and washed 10 times with PBST.
Thirty Al per well of activator mix (U-Cytech) was then
added and developed for 30 min to allow formation of silver
salt precipitate at the site of gold clusters. Wells were then
washed with distilled water and air-dried, and spots were
counted with a KS ELISPOT Automated Reader System
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software (performed by Zellnet, New York, NY). Results are
presented as the frequency of SIV-specific spot forming
cells (SFC) per 106 PBMC minus the frequency of SFC per
106 PBMC obtained with NYCBH infection. Calculated
frequencies were based on the average of the duplicate wells
plated at 3  105 and 1  105 cells per well; the frequency
of SFC calculated from wells plated at 3  104 cells per well
was included in the calculation of SFC only if N10
spots per well were observed.
SIV-specific CTL assays
CTL activity was measured as previously described
(Johnson et al., 1997). Briefly, PBMC were isolated from
CPT Vacutainer tubes centrifuged at 2800 rpm for 30 min at
room temperature and then suspended at 2  106 cells/ml in
RPMI 1640 medium (Life Technologies, Gaithersburg, MD)
supplemented with 10% FBS (Sigma, St. Louis, MO), 10
mM HEPES, 2 mM l-glutamine, 50 IU of penicillin/ml, and
50 Ag of streptomycin/ml (R-10). Herpesvirus papio-trans-
formed B cell lines (B-LCL) were prepared from PBMC as
described previously (Johnson et al., 1997) and propagated
in RPMI 1640 medium supplemented with 20% FBS.
Autologous B-LCL infected with control vaccinia virus
NYCBH or a recombinant vaccinia virus (vAbt388;
provided by D. Panicali, Therion Biologics, Cambridge,
Mass.) containing the SIVmac251 gag and pol genes and
the SIVmac 239 env gene were used. After a 90-min
incubation with vaccinia virus, cells were washed once and
used as stimulators. The PBMC were mixed with stimula-
tors in R-10 at a concentration of 2  106/ml at a responder
to stimulator ratio of 10:1 and incubated at 37 8C in a 5%
CO2 incubator. Cell cultures were fed with R-10 medium
twice a week and recombinant human IL-2 (final concen-
tration 20 U/ml) was added to the medium after 4–5 days.
CTL assays were performed 10–14 days after stimulation.
Target cells consisted of autologous B-LCL infected with
individual recombinant vaccinia viruses expressing the SIV
Gag derived from SIVmac251, or the Gag and Pol proteins
derived from the SIVsmH4 clone. SIVsmH4, which is more
closely related to the SIVsmE660 virus than SIVmac239
(Hirsch et al., 1989), is a molecular clone of SIV derived
from a macaque that developed AIDS after being exper-
imentally inoculated with SIV from an asymptomatic sooty
mangabey. The unmodified vaccinia virus NYCBH was
used as a control. Target cells were infected overnight at a
multiplicity of infection of 5–10 PFU/cell and then labeled
with 50 ACi 51Cr (DuPont-NEN, Wilmington, DE)/106 cells.
Target cells (104 cells/well) were dispensed in triplicate for
each E/T cell ratio into 96-well U-bottom plates (Costar,
Cambridge, MA). Cold target inhibition was used in all
assays to decrease background lysis. Cold targets consisted
of unlabeled autologous B-LCL that had been infected with
the control vaccinia virus NYCBH and were used at a cold/
hot target ratio of 15:1. Chromium release was assayed aftera 5-h incubation at 37 8C in a 5% CO2 incubator. Plates
were spun at 1000 rpm for 10 min at 4 8C, after which 30 Al
of supernatant was harvested from each well onto wells of a
LumaPlate-96 (Packard) and allowed to dry overnight.
Emitted radioactivity was measured in a 1450 MicroBeta
Plus Liquid Scintillation Counter (Wallac, Turku, Finland).
Spontaneous release was measured from wells containing
only target cells and medium. Maximum release was
measured from wells containing target cells and 0.1%
Triton X-100 (Sigma). The percent cytotoxicity was calcu-
lated as follows: ((test release  spontaneous release) /
(maximum release  spontaneous release))  100%. Spon-
taneous release of target cells was b25% in all assays.
Measurement of humoral responses
Plasma samples were analyzed for reactivity to SIV
envelope glycoproteins (gp120 and gp41) in a concanavalin
A (ConA) ELISA as described previously (Cole et al.,
1997). Briefly, endpoint titers to viral envelope glycopro-
teins are reported as the last serial 2-fold dilution with an
optical density twice that of uninfected monkey serum, or an
optical density of 0.1, whichever value was greater.
Neutralizing antibodies were measured in a CEMx174
cell-killing assay as described (Montefiori et al., 1996).
Titers of neutralizing antibodies are reported as the
reciprocal plasma dilution at which 50% of cells were
protected from virus-induced killing as measured by neutral
red uptake. A 50% reduction in cell-killing corresponds to
an approximate 90% reduction in viral Gag antigen
synthesis in this assay (Ourmanov et al., 2000). Assays
stocks of virus were generated in human PBMC (SIV-
mac239/nef-open), CEMx174 cells (SIVsmE660) and H9
cells (TCLA SIVmac251). Plasma samples were heat-
inactivated for 1 h at 56 8C prior to assay.Acknowledgments
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